These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20203507)

  • 21. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management.
    Quigley EM
    J Dig Dis; 2007 Feb; 8(1):2-7. PubMed ID: 17261128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of probiotics in IBS.
    Quigley EM
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S85-90. PubMed ID: 18542036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment options in irritable bowel syndrome.
    Farthing MJ
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):773-86. PubMed ID: 15324713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.
    Buhner S; Li Q; Vignali S; Barbara G; De Giorgio R; Stanghellini V; Cremon C; Zeller F; Langer R; Daniel H; Michel K; Schemann M
    Gastroenterology; 2009 Oct; 137(4):1425-34. PubMed ID: 19596012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study.
    Corinaldesi R; Stanghellini V; Cremon C; Gargano L; Cogliandro RF; De Giorgio R; Bartesaghi G; Canovi B; Barbara G
    Aliment Pharmacol Ther; 2009 Aug; 30(3):245-52. PubMed ID: 19438846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Vivinus-Nébot M; Dainese R; Anty R; Saint-Paul MC; Nano JL; Gonthier N; Marjoux S; Frin-Mathy G; Bernard G; Hébuterne X; Tran A; Theodorou V; Piche T
    Am J Gastroenterol; 2012 Jan; 107(1):75-81. PubMed ID: 21931380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathophysiology of irritable bowel syndrome.
    Schwetz I; Bradesi S; Mayer EA
    Minerva Med; 2004 Oct; 95(5):419-26. PubMed ID: 15467517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome.
    La JH; Kim TW; Sung TS; Kim HJ; Kim JY; Yang IS
    J Vet Sci; 2004 Dec; 5(4):319-24. PubMed ID: 15613815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.
    Piche T; Barbara G; Aubert P; Bruley des Varannes S; Dainese R; Nano JL; Cremon C; Stanghellini V; De Giorgio R; Galmiche JP; Neunlist M
    Gut; 2009 Feb; 58(2):196-201. PubMed ID: 18824556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment.
    Chang JY; Talley NJ
    Trends Pharmacol Sci; 2010 Jul; 31(7):326-34. PubMed ID: 20554042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell activation in patients with irritable bowel syndrome (IBS).
    Ohman L; Lindmark AC; Isaksson S; Posserud I; Strid H; Sjövall H; Simrén M
    Neurogastroenterol Motil; 2009 Jun; 21(6):644-50, e27. PubMed ID: 19222763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is irritable bowel syndrome a low-grade inflammatory bowel disease?
    Bercik P; Verdu EF; Collins SM
    Gastroenterol Clin North Am; 2005 Jun; 34(2):235-45, vi-vii. PubMed ID: 15862932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.
    Lee KJ; Kim YB; Kim JH; Kwon HC; Kim DK; Cho SW
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1689-94. PubMed ID: 19120860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Postinfectious irritable bowel syndrome].
    Döbrönte Z; Lakner L; Sarang K
    Orv Hetil; 2006 Oct; 147(43):2077-80. PubMed ID: 17297754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.
    Bittner AC; Croffut RM; Stranahan MC
    Clin Ther; 2005 Jun; 27(6):755-61. PubMed ID: 16117982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.
    Camilleri M
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S123-5. PubMed ID: 18806702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New pathophysiological mechanisms in irritable bowel syndrome.
    Barbara G; De Giorgio R; Stanghellini V; Cremon C; Salvioli B; Corinaldesi R
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():1-9. PubMed ID: 15335408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome.
    Piche T; Saint-Paul MC; Dainese R; Marine-Barjoan E; Iannelli A; Montoya ML; Peyron JF; Czerucka D; Cherikh F; Filippi J; Tran A; Hébuterne X
    Gut; 2008 Apr; 57(4):468-73. PubMed ID: 18194987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.